Hormone sensitive protocol for metastatic prostate cancer, an update

被引：0

作者：

Ossorioa, J. L. Alvarez ^{[1
,2
,3
]}

Aliagac, M. Rodrigo ^{[4
]}

Antolind, A. Rodriguez ^{[5
]}

Urzaize, M. Unda ^{[6
]}

Callejaf, M. A.

Ruizg, M. de la Cruz ^{[7
]}

Quilezh, J. Blas ^{[8
]}

Millani, I. R. Hernandez ^{[9
]}

Zalabardoj, D. Sanchez ^{[10
]}

Olmo, J. M. Cozar

机构：

[1] Hosp Univ Puerta Mar, Serv Urol, Cadiz, Spain

[2] Asociac Espanola Urol AEU, Madrid, Spain

[3] Fdn Invest Urol FIU, Madrid, Spain

[4] Hosp Gen Univ Castellon, Serv Urol, Castellon de La Plana, Spain

[5] Hosp Univ 12 Octubre, Serv Urol, Madrid, Spain

[6] Hosp Univ Basurto, Serv Urol, Bilbao, Vizcaya, Spain

[7] Hosp Son Espases, Serv Urol, Palma De Mallorca, Baleares, Spain

[8] Hosp Univ Virgen Salud, Complejo Hosp Toledo, Toledo, Spain

[9] Hosp Univ Albacete, Albacete, Spain

[10] Hosp Reina Sofia, Navarra, Spain

来源：

ACTAS UROLOGICAS ESPANOLAS | 2023年 / 47卷 / 04期

关键词：

Androgen deprivation therapy; Clinical follow-up; Hormone sensitive metastatic prostate cancer; Treatment; ANDROGEN DEPRIVATION THERAPY;

D O I：

10.1016/j.acuro.2022.09.003

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

To review and update last protocols in hormone sensitive metastatic prostate cancer for improving clinical management in routine. Evidence analysis available about recent updates protocols in hormone sensitive metastatic prostate cancer according to expert panel of clini-cians about this field. A nominal consensus group for unify and improve the recommendations to the management of sensitive metastatic prostate cancer patients is currently needed. This document unifies and improve the management of patients with hormone sensitive metastatic prostate cancer, with a methodology that combines data quantitative and qualitative and based on the participation of a broad scientific committee appointed by the Spanish Association of Urology. (c) 2022 AEU. Published by Elsevier Espan similar to a, S.L.U. All rights reserved.

引用

页码：244 / 249

页数：6

共 50 条

[1] Update on Metastatic Hormone-Sensitive Prostate Cancer
Chi, Kim N.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (05) : 277 - 280
[2] Management of hormone-sensitive metastatic prostate cancer - Update on hormonal therapy
Figg, WD
Feuer, JA
Bauer, KS
CANCER PRACTICE, 1997, 5 (04) : 258 - 263
[3] French CCAFU guidelines on prostate cancer: hormone-sensitive metastatic prostate cancer-update 2020
Rozet, F.
Hennequin, C.
Beuzeboc, P.
Mathieu, R.
Mongiat-Artus, P.
Beauval, J-B
Cormier, L.
Fromont-Hankard, G.
Ploussard, G.
Renard-Penna, R.
Brureau, L.
Mejean, A.
PROGRES EN UROLOGIE, 2020, 30 (8-9): : 430 - 438
[4] Metastatic hormone-sensitive prostate cancer
Gravis, Gwenaelle
Salem, Naji
Walz, Jochen
BULLETIN DU CANCER, 2015, 102 (01) : 57 - 64
[5] Rezvilutamide for metastatic hormone-sensitive prostate cancer
Ye, Dingwei
Gu, Weijie
Li, Junliang
LANCET ONCOLOGY, 2022, 23 (11): : E491 - E491
[6] Treatment of metastatic hormone-sensitive prostate cancer
Rane, Jayant K.
Chowdhury, Amani
Kinnaird, William
Marks, Gillian
Davda, Reena
TRENDS IN UROLOGY & MENS HEALTH, 2021, 12 (06) : 7 - 10
[7] Docetaxel for hormone-sensitive metastatic prostate cancer
Baker, Holly
LANCET ONCOLOGY, 2015, 16 (09): : E432 - E432
[8] Management of Metastatic Hormone-Sensitive Prostate Cancer
Bernard, Brandon
Sweeney, Christopher J.
CURRENT UROLOGY REPORTS, 2015, 16 (03)
[9] Management of Hormone-Sensitive Metastatic Prostate Cancer
Agarwal, Neeraj
Hussain, Maha
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (06) : 1221 - +
[10] Management of Metastatic Hormone-Sensitive Prostate Cancer
Brandon Bernard
Christopher J. Sweeney
Current Urology Reports, 2015, 16

← 1 2 3 4 5 →